SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:su-219187"
 

Sökning: onr:"swepub:oai:DiVA.org:su-219187" > Impact of the Mean ...

  • Tuleasca, ConstantinLausanne University Hospital (CHUV), Neurosurgery Service and Gamma Knife Center, Lausanne, Switzerland;;University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Lausanne, Switzerland;;Ecole Polytechnique Fédérale de Lausanne (EPFL, LTS-5), Lausanne, Switzerland; (författare)

Impact of the Mean Cochlear Biologically Effective Dose on Hearing Preservation After Stereotactic Radiosurgery for Vestibular Schwannoma: A Retrospective Longitudinal Analysis

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:su-219187
  • https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-219187URI
  • https://doi.org/10.1227/neu.0000000000002609DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154933290URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-507817URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is a useful alternative for small- to medium-sizedvestibular schwannoma. To evaluate whether biologically effective dose (BEDGy2.47), calculated for mean (BEDGy2.47 mean)and maximal (BEDGy2.47 max) cochlear dose, is relevant for hearing preservation. METHODS: This is a retrospective longitudinal single-center study. Were analyzed 213 patients with useful baselinehearing. Risk of hearing decline was assessed for Gardner–Robertson classes and pure tone average (PTA) loss. The meanfollow-up period was 39 months (median 36, 6-84).RESULTS: Hearing decline (Gardner–Robertson class) 3 years after SRS was associated with higher cochlear BEDGy2.47 mean(odds ratio [OR] 1.39, P = .009). Moreover, BEDGy2.47 mean was more relevant as compared with BEDGy2.47 max (OR 1.13, P = .04).Risk of PTA loss (continuous outcome, follow-up minus baseline) was significantly corelated with BEDGy2.47 mean at 24 (betacoefficient 1.55, P = .002) and 36 (beta coefficient 2.01, P = .004) months after SRS. Risk of PTA loss (>20 dB vs ≤) was associatedwith higher BEDGy2.47 mean at 6 (OR 1.36, P = .002), 12 (OR 1.36, P = .007), and 36 (OR 1.37, P = .02) months. Risk of hearingdecline at 36 months for the BEDGy2.47 mean of 7–8, 10, and 12 Gy2.47 was 28%, 57%, and 85%, respectively. CONCLUSION: Cochlear BEDGy2.47 mean is relevant for hearing decline after SRS and more relevant as compared withBEDGy2.47 max. Three years after SRS, this was sustained for all hearing decline evaluation modalities. Our data suggestthe BEDGy2.47 mean cut-off of ≤8 Gy2.47 for better hearing preservation rates.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Toma-Daşu, Iuliana,1972-Stockholms universitet,Fysikum,Oncology Pathology Department, Karolinska Institutet, Stockholm, Sweden;;Medical Radiation Physics, Stockholm University, Stockholm, Sweden;(Swepub:su)iuda0736 (författare)
  • Duroux, SebastienUniversity of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Lausanne, Switzerland; (författare)
  • George, MercyENT Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland; (författare)
  • Maire, RaphaelENT Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland; (författare)
  • Daniel, Roy ThomasLausanne University Hospital (CHUV), Neurosurgery Service and Gamma Knife Center, Lausanne, Switzerland;;University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Lausanne, Switzerland; (författare)
  • Patin, DavidInstitute of Radiation Physics, Lausanne, Switzerland; (författare)
  • Schiappacasse, LuisRadiation Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland; (författare)
  • Dasu, AlexandruThe Skandion Clinic, Uppsala, Sweden;;Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;(Swepub:uu)aleda511 (författare)
  • Faouzi, MohamedDivision of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland (författare)
  • Levivier, MarcLausanne University Hospital (CHUV), Neurosurgery Service and Gamma Knife Center, Lausanne, Switzerland;;University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Lausanne, Switzerland;;Ecole Polytechnique Fédérale de Lausanne (EPFL, LTS-5), Lausanne, Switzerland; (författare)
  • Lausanne University Hospital (CHUV), Neurosurgery Service and Gamma Knife Center, Lausanne, Switzerland;;University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Lausanne, Switzerland;;Ecole Polytechnique Fédérale de Lausanne (EPFL, LTS-5), Lausanne, Switzerland;Fysikum (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neurosurgery94:1, s. 174-1820148-396X1524-4040

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy